Cullinan Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Cullinan Therapeutics, Inc. carries a market capitalization of 841.97M, placing it among publicly traded companies globally. Its enterprise value stands at 494.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 841.97M |
| Enterprise Value | 494.67M |
Share Statistics
Cullinan Therapeutics, Inc. currently has 61.45M shares outstanding.
| Shares Outstanding | 61.45M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.32 |
| P/TBV Ratio | 2.31 |
| P/FCF Ratio | -4.73 |
| P/OCF Ratio | -4.73 |
Financial Position
Cullinan Therapeutics, Inc. maintains a current ratio of 10.28, meaning it holds 10.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.28 |
| Quick Ratio | 10.01 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -44.99 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Cullinan Therapeutics, Inc.'s stock has gained approximately 56.75057% over the past 52 weeks. The 50-day moving average sits at 14.48, while the 200-day moving average is 11.29.
| Beta (5Y) | N/A |
| 52-Week Price Change | 56.75057% |
| 50-Day Moving Average | 14.48 |
| 200-Day Moving Average | 11.29 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -240.03M, while operating income came in at -240.35M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -240.35M |
| Pretax Income | -221.04M |
| Net Income | -221.04M |
| EBITDA | -240.03M |
| EBIT | -240.35M |
| Earnings Per Share (EPS) | -3.72 |
Balance Sheet
Cullinan Therapeutics, Inc. holds 351.89M in cash and equivalents against 2.38M in total debt, resulting in a net debt position of -75.08M. Total book value stands at -637.77M, with working capital of 326.25M providing operational flexibility.
| Cash & Cash Equivalents | 351.89M |
| Total Debt | 2.38M |
| Net Debt | -75.08M |
| Equity (Book Value) | -637.77M |
| Book Value Per Share | -10.74 |
| Working Capital | 326.25M |
Cash Flow
Cullinan Therapeutics, Inc. produced -178.64M in operating cash flow over the past twelve months. After subtracting -11,000.00 in capital expenditures, free cash flow totaled -178.65M - equivalent to -3.01 per share.
| Operating Cash Flow | -178.64M |
| Capital Expenditures | -11,000.00 |
| Free Cash Flow | -178.65M |
| FCF Per Share | -3.01 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.17 |
| FCF Yield | -21.16 |
Scores
Cullinan Therapeutics, Inc. posts an Altman Z-Score of 10.55, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 10.55 |